ChIP-Seq for ER and FOXA1 in breast cancer tumors and cell lines.
Samples include eight primary tumors from patients with good prognosis (ER+ PR+ HER2-),
seven primary tumors from patients with poor outcome (ER+ PR- HER2- or ER+ PR+ HER2+), three ER+ distant metastases,
two ER- tumors, and five breast cancer cell lines grown under two different different conditions. Input used as control.
Source
Raw data was downloaded from GEO series:
GSE322222
Tumor identifiers were taken from GEO sample documentation.
We were unable to match the names used in Ross-Innes et al. 2012 (G1, G2, etc.) with those provided by GEO (e.g. BT81583).
The nomenclature of cell lines and conditions is based on Supplementary figure 2 from Ross-Innes et al. 2012.
Technical Notes
The sga files were automatically generated from the original BAM files providing the starting and ending postions
of mapped sequence tags in the human genome assembly 2006 (NCBI36/hg18).
References
Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, Ali S, Chin SF, Palmieri C, Caldas C, Carroll JS Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.
Nature. 2012 Jan 4;481(7381):389-93. doi: 10.1038/nature10730.
22217937
GEO series
GSE32222:
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer